J. A. Duce, A. Tsatsanis, M. A. Cater, S. A. James, E. Robb, K. Wikhe ,S. L. Leong, K. Perez, T. Johanssen, M. A. Greenough, H. H. Cho, D. Galatis,R. D. Moir, C. L. Masters, C. Mclean, R. E. Tanzi, R. Cappai, K. J. Barnham, G. D. Ciccotosto, J. T. Rogers and A. I. Bush, “Iron-Export Ferroxidase Activity of β-Amyloid Precursor Protein is Inhibited by Zinc in Alzheimer’s Disease,” Cell, Vol. 142, No. 6, 2010, pp. 857-867. doi:10.1016/j.cell.2010.08.014

has been cited by the following article:

• TITLE: The Functions of the Amyloid Precursor Protein Gene and Its Derivative Peptides: III Pharmacological Studies

  AUTHORS: Peter K. Panegyres, Emily R. Atkins

  KEYWORDS: Amyloid Precursor Protein, APP, Genes, Dementia, Alzheimer’s Disease

  JOURNAL NAME: Neuroscience and Medicine, Vol.2 No.4, December 2, 2011

  ABSTRACT: Pharmacological studies reveal APP and Aβ have interactions with glutamate and calcium, cytokines, copper/zinc chelators, secretases and presenilins, nicotinic receptors, acetycholinesterase, neurotrophins, non-steroidal anti-inflame-matory drugs, monoclonal antibodies to Aβ, protease inhibitors, oestrogen, homocysteine, immediate early genes such as c-fos or c-jun and cholesterol. These functional and pharmacological observations highlight the need for greater understanding of APP and Aβ in brain function and have implications for clinical trials.